DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

Dow Jones

Oct 23, 2024

By Sabela Ojea

Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch.

The stock was up 47% to $1.03 in post-market trading on Tuesday. The stock has fallen 26% in the past three months, and 61% this year.

The clinical-stage biopharmaceutical company said it has agreed to guidance provided by the Food and Drug Administration on a pathway under the accelerated approval program for the Viaskin Peanut patch in toddlers ages 1 to 3 years old.

DBV said it intends to formalize the accelerated approval guidance by submitting a meeting request. Additionally, the company said it expects the confirmatory study to be initiated by the time of the Biologics License Applications submission, which would run in parallel to commercialization in the U.S. if the patch is approved.

The company also said it received scientific advice from the European Medicines Agency on an indication for children 1 to 7 years old for the peanut allergy treatment.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 22, 2024 17:22 ET (21:22 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2477739927"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2477739927\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2477739927?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-23 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477739927","market":"fut","top_or_hot":-1,"title":"DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch. \n</p>\n<p>\n  The stock was up 47% to $1.03 in post-market trading on Tuesday. The stock has fallen 26% in the past three months, and 61% this year. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it has agreed to guidance provided by the Food and Drug Administration on a pathway under the accelerated approval program for the Viaskin Peanut patch in toddlers ages 1 to 3 years old. \n</p>\n<p>\n  DBV said it intends to formalize the accelerated approval guidance by submitting a meeting request. Additionally, the company said it expects the confirmatory study to be initiated by the time of the Biologics License Applications submission, which would run in parallel to commercialization in the U.S. if the patch is approved. \n</p>\n<p>\n  The company also said it received scientific advice from the European Medicines Agency on an indication for children 1 to 7 years old for the peanut allergy treatment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2024 17:22 ET (21:22 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-23 05:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch. \n</p>\n<p>\n  The stock was up 47% to $1.03 in post-market trading on Tuesday. The stock has fallen 26% in the past three months, and 61% this year. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it has agreed to guidance provided by the Food and Drug Administration on a pathway under the accelerated approval program for the Viaskin Peanut patch in toddlers ages 1 to 3 years old. \n</p>\n<p>\n  DBV said it intends to formalize the accelerated approval guidance by submitting a meeting request. Additionally, the company said it expects the confirmatory study to be initiated by the time of the Biologics License Applications submission, which would run in parallel to commercialization in the U.S. if the patch is approved. \n</p>\n<p>\n  The company also said it received scientific advice from the European Medicines Agency on an indication for children 1 to 7 years old for the peanut allergy treatment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 22, 2024 17:22 ET (21:22 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2477739927","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477739927","pubTimestamp":1729632120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch.The stock was up 47% to $1.03 in post-market trading on Tuesday. The stock has fallen 26% in the past three months, and 61% this year.The clinical-stage biopharmaceutical company said it has agreed to guidance provided by the Food and Drug Administration on a pathway under the accelerated approval program for the Viaskin Peanut patch in toddlers ages 1 to 3 years old.DBV said it intends to formalize the accelerated approval guidance by submitting a meeting request. Additionally, the company said it expects the confirmatory study to be initiated by the time of the Biologics License Applications submission, which would run in parallel to commercialization in the U.S. if the patch is approved.The company also said it received scientific advice from the European Medicines Agency on an indication for children 1 to 7 years old for the peanut allergy trea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DBVT":"DBV Technologies S.A.","DBV":"Invesco DB G10 Currency Harvest Fund"},"translate_title":"花生过敏贴片积极更新后，DBV Technologies股价上涨47%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBVT":0.9,"DBV":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of DBV Technologies surged after it received positive regulatory updates in the U.S. and Europe for its Viaskin Peanut allergy patch. \n\n\n  The stock was up 47% to $1.03 in post-market trading on Tuesday. The stock has fallen 26% in the past three months, and 61% this year. \n\n\n  The clinical-stage biopharmaceutical company said it has agreed to guidance provided by the Food and Drug Administration on a pathway under the accelerated approval program for the Viaskin Peanut patch in toddlers ages 1 to 3 years old. \n\n\n  DBV said it intends to formalize the accelerated approval guidance by submitting a meeting request. Additionally, the company said it expects the confirmatory study to be initiated by the time of the Biologics License Applications submission, which would run in parallel to commercialization in the U.S. if the patch is approved. \n\n\n  The company also said it received scientific advice from the European Medicines Agency on an indication for children 1 to 7 years old for the peanut allergy treatment. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2024 17:22 ET (21:22 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}